dr. M.L. (Marianne) Boes
- Laboratory for Translational Immunology (LTI)
- Immunology research 1
Marianne Boes trained in the USA in immunology and cell biology research (1996-2008). She performed PhD research at Massachusetts Institute of Technology (MIT), at the Koch Institute for integrative Cancer Research under supervision of prof. Jianzhu Chen. Here she studied immunodeficiency mechanisms using mouse models. Postdoctoral work she performed at Harvard Medical School in the laboratory of prof. Hidde Ploegh, where she discovered the rapid and dynamic endosomal remodeling process in dendritic cells that occurs immediately upon antigen-specific T-cell contact (Boes et al, Nature 2002). In 2004, Dr. Boes started her independent research lab at Brigham and Women’s Hospital/Harvard Medical School, financed in part by an NWO-Veni grant in 2004 and a large NIH-RO1 grant that was awarded to her. In 2008, she moved her lab to the UMC-Utrecht.
Boes heads the pediatric immunology laboratory at the UMC Utrecht, embedded in the Center for Translational Immunology. She published more than 120 articles (H-index approaching 40) in international journals, including Nature, Science, Immunity, J. Exp. Med., Nature Immunology and J. Clin. Invest. She and her group received numerous prestigious national and international grants and awards. Boes serves as editor for several peer-reviewed journals and is a regular reviewer for major journals in her field.
She is Chair of the Young Academy of the UMC Utrecht and board member of the Center for Unusual Collaborations (CUCo; working group of the Young Academies of the Strategic Alliance between TU-Eindhoven, Wageningen, Utrecht University and UMC-Utrecht). Boes is Faculty of Medicine-biomedical sciences member of the Education Committee of the Graduate School of Life Sciences (EC-LS), and serves as coordinator of the course 'Advanced Immunology' for PhD students, and the MSc course Logical Argumentation in Science: Publishing, Proposals and Pitching (co-coordinating with Eric Kalkhoven). She is current member of the I&I graduate school teaching committee. She thoroughly enjoys to meet and learn from researchers, patients and societal partners in different fields. She works actively to improve the involvement of patients and their perspectives in translational research.
The inadequate use of immune pathways can result in disease, such as exemplified in primary immunodeficiency patients. Boes focuses her translational research on the control of antigen-specific immune activation. Approaches include the study of immune cell function of patients suffering from autoimmune forms of arthritis, the study of immune tolerance mechanisms in hemophilia A patients receiving live-long supplementation therapy, and discovery of lymphoma-expressed neoantigens in primary tumor tissue to apply in therapeutic vaccination. The overarching goal is to develop new therapies for immune-mediated disorders such as psoriatic arthritis, of hemophilia A patients developing complications (to remove FVIII-neutralizing 'inhibitor' antibodies) and pediatric cancers.
Research in Boes lab is supported financially by grants from NWO, the European Research Council (ERC), the Lymph&co foundation, the strategic alliance TUe, WUR, UU, UMCU (The Power-Of-One project) and industry partners. Boes collaborates across disciplines with investigators, societal partners and patientgroups at the UMC-Utrecht and beyond. Several collaborative projects exist with labs elsewhere in Europe and in the USA.
ZonMw member of the External Evaluation Committee Translationeel onderzoek, Oct 2019- Feb 2021
ZonMw member of evaluation committee COVID19 studies, 2020 - current
DSMB member COVID vaccination study LUMC
GSLS staf member educational committee (Faculty of Medicine - Biomedical Sciences), 2017- current
Member scientific evaluation committee Horizon 2020 grants ERA-NET 2015 and 2016
NVVI member financial committee 'kascommissie' (Dutch Society for Immunology)
Member of the NVVI and BSI, Dutch and British Society for Immunology
Editorial Board member: Immunotherapy Advances (Oxford Academic Press)
Editorial Board member: Immunology Letters (Elsevier)
Associate editor and frequent reviewer of various immunology and cancer-related journals
2018/2021: member of various PhD thesis defense committees Radboud University, VUMC, AMC and UU
2016-2018: invited speaker: Boston Children's Hospital; FASEB conference (SRC Immunoreceptors, Colorado); Instituto Gulbenkian de Ciência, Portugal; Charles University Prague PhD conference; European Conference of Immunology; European B cell forum 2018 Landshut Germany, IUIS Beijing (also session chair)
2020-2021: invited speaker (live and webinar-based): Vienna Medical University, colloquium in pathophysiology, infectiology and immunology; 14th EFIS-EJI Tatra Immunology Conference, September 19-23, 2020; summer school Bonn University Cluster of Excellence; 50th anniversary meeting of the Scandinavian Society for Immunology; Immunometnet
Fellowship and Awards
2021: Actuate grant 200K dollar (PI)
2021: EWUU-Unusual Collaboration grant; 168K (co-PI)
2021: ARGENX grant: 568K (PI)
2021: JMF-c.h.i.l.d.r.e.n. 50K (co-PI)
2020: travel award Beijing IUIS conference 2K (PI)
2020: Actuate grant 100K dollar (PI)
2019: Lymph&co 385K (PI)
2019: Nutricia 47.5K (co-PI)
2018: Child Health focus grant 15K (co-PI)
2018: Nutricia 47.5K (co-PI)
2017: Sobi 42.6K (co-PI)
2015: UU Life Sciences Seed grant 100K (co-PI)
2015: Fonds NutsOhra 67K (co-PI)
2014: NWO-PhD grant 250K (I&I graduate school UU)
2014: WKZ Research Foundation 38K (PI)
2014: Diabetes Fonds Nederland 250K (co-PI)
2013: Bayer 574K (co-PI)
2012: NWO investment subsidy medium 586K (co-PI)
2012: Fonds NutsOhra 100K (co-PI)
2011: MedImmune research grant 75K (PI)
2011: Baxalta (now part of Takeda) 273K (co-PI)
2010: ERC-Marie Curie 80K (PI)
2009 WKZ Research Foundation 150K (PI)
2009 UMCU Talent incentive 250K (PI)
2008 WKZ Research Foundation 125K (PI)
2008 Baxalta (now part of Takeda) 230K (co-PI)
2007: NIH-RO1 grant 750K (PI)
2006: Harvard Skin Disease Research Center grant 25K (PI)
2004: NWO-Veni 250K (PI)
2001: Cancer Research Institute/ Irvington fellowship 300K (PI)
1997: Boehringer Ingelheim PhD fellowship 250K (PI)
Research Output (157)
Schep Sarah, Schutgens Roger E, Fischer Kathelijn, Voorberg Jan, Boes Marianne mei 2021, In: Hemasphere. 5 9 p.
Greve Patrick, Meyer Wentrup Friederike, Peperzak Victor, Boes Marianne jan 2021, In: Immunotherapy Advances. 1 14 p.
Silva-Cardoso Sandra C., Tao Weiyang, Angiolilli Chiara, Lopes Ana P., Bekker Cornelis P. J., Devaprasad Abhinandan, Giovannone Barbara, van Laar Jaap, Cossu Marta, Marut Wioleta, Hack Erik, de Boer Rob J., Boes Marianne, Radstake Timothy R. D. J., Pandit Aridaman 17 sep 2020, In: Frontiers in Immunology. 11
Jansen AJ Gerard, Spaan Thom, Low Hui Zhi, Di lorio Daniele , van den Brand Judith M A, Tieke Malte, Barendrecht Arjan , Rohn Kerstin, van Amerongen Geert, Stittelaar Koert, Baumgartner Wolfgang , Osterhaus Albert D M E, Kuiken Thijs, Boons Geert-Jan, Huskens Jurriaan , Boes Marianne, Maas Coen, van der Vries Erhard 14 jul 2020, In: Blood Advances. 4 , p. 2967-2978 12 p.
Silva-Cardoso Sandra C, Tao Weiyang, Fernández Beatriz Malvar, Boes Marianne, Radstake Timothy R D J, Pandit Aridaman 5 jun 2020, In: European Journal of Immunology. 50 , p. 1598-1601 4 p.
Ohradanova-Repic Anna, Boes Marianne, Stockinger Hannes 24 mrt 2020, In: Frontiers in Immunology. 11
van Kempen Tessa S, Leijten Emmerik F A, Lindenbergh Marthe F S, Nordkamp Michel Olde, Driessen Christoph, Lebbink Robert-Jan, Baerlecken Niklas, Witte Torsten, Radstake Timothy R D J, Boes Marianne 21 mrt 2020, In: European Journal of Immunology. 50 , p. 1209-1219 11 p.
Lindenbergh Marthe F S, Wubbolts Richard, Borg Ellen G F, van 't Veld Esther M, Boes Marianne, Stoorvogel W 1 jan 2020, In: Journal of Extracellular Vesicles. 9
Pouw Juliëtte, Leijten Emmerik, Radstake Timothy, Boes Marianne 26 nov 2019, In: Clinical Immunology. 211 8 p.
Silva-Cardoso Sandra C., Bekker Cornelis P.J., Boes Marianne, Radstake Timothy R.D.J., Angiolilli Chiara 10 sep 2019, In: Molecular Immunology. 114 , p. 524-534 11 p.